Related Experiment Videos
Overview of recurrent respiratory papillomatosis
1Department of Pediatrics and Surgery, University of Alabama at Birmingham, USA. brian.wiatrak@chsys.org
Insights
Pediatric recurrent respiratory papillomatosis (RRP) remains a challenging disease. Recent advancements in surgical techniques, medical therapies, and immunologic research offer promising new avenues for managing this condition in children.
Area of Science:
- Otolaryngology
- Pediatric Medicine
- Immunology
Background:
- Pediatric recurrent respiratory papillomatosis (RRP) presents a significant management challenge for otolaryngologists.
- The condition imposes a substantial burden on healthcare systems and causes considerable morbidity in affected children and their families.
- The incidence of pediatric RRP is approximately 3.96 per 100,000, with a notable risk observed in children born to mothers with vaginal condyloma.
Purpose of the Study:
- To review recent literature on pediatric recurrent respiratory papillomatosis (RRP) published within the last year.
- To enhance understanding of the etiology and management of pediatric RRP.
- To provide physicians with updated information for improved patient care.
Main Methods:
- Literature review of articles published within the last year.
- Assessment of current and emerging surgical techniques.
- Evaluation of adjuvant medical therapies and novel treatments, including vaccine therapy and immunologic research.
Main Results:
- While the CO2 laser remains a mainstay, powered instrumentation and pulse-dye laser show efficacy in surgical management.
- Traditional therapies like interferon-alpha2a, retinoic acid, and I3C/DIM are still used, with cidofovir showing promise in select cases.
- Immunologic research has identified cell-mediated immunity defects, shedding light on RRP etiology and suggesting potential for immune modulation therapies.
Conclusions:
- Pediatric RRP is a highly morbid disease requiring ongoing research and therapeutic innovation.
- New surgical and medical interventions offer improved disease control prospects.
- Advances in immunologic research hold potential for future treatment strategies involving immune system modulation.
Purpose Of Review:
The purpose of this article is to review recent literature regarding pediatric recurrent respiratory papillomatosis (RRP) published within the last year. By reviewing and assessing these articles, a more clear understanding regarding the etiology and management of pediatric RRP can be obtained, allowing physicians to better care for their pediatric RRP patients.
Recent Findings:
Pediatric RRP continues to be an extremely difficult management problem for otolaryngologists. This disease process continues to be a significant burden on the health care system and is a significant cause of morbidity in affected patients and their families. The incidence of RRP continues to be approximately 3.96 per 100,000 in the pediatric population. It has been noted recently that approximately 7 of every 1000 children born to mothers with vaginal condyloma develop pediatric RRP. Although the mainstay of surgical management has traditionally been the CO2 laser, newer surgical techniques have demonstrated efficacy in the management of pediatric RRP patients, including powered instrumentation and the pulse-dye laser. The traditional adjuvant medical therapies used for pediatric RRP continue to be commonly used, including interferon-alpha2a, retinoic acid, and indol-3-carbinol/diindolylmethane (I3C/DIM). Recently cidofovir has demonstrated efficacy in selected patients. In addition, current research regarding vaccine therapy for pediatric RRP has shown promise. Basic science research in the field of immunology has demonstrated multiple defects in cell-mediated immunity, which has shed further light on the etiology of pediatric RRP.
Summary:
Pediatric RRP continues to be a highly morbid disease process. New surgical and medical therapies offer hope for better control of this disease in affected patients. Recent advances in immunologic research offer the hope of immune system modulation and augmentation as potential future treatment modalities to better control this disease process.